Are higher vancomycin doses needed in venticle-external shunted patients?

Pharmacy World and Science

Volumn 28, Issue 4, 2006, Pages 215-221

  Pujal, Meritxell ^a   Soy, Dolors ^a   Codina, Carles ^a   Ribas, Josep ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Hydrocephalus; Optimal dosage; Pharmacokinetic parameters; TDM; Therapeutic Drug Monitoring; Vancomycin; Ventricle external shunt

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; FEMALE; HEART VENTRICLE; HUMAN; HYDROCEPHALUS; INTENSIVE CARE UNIT; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; SHUNTING; STEADY STATE; UNIVERSITY HOSPITAL;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID SHUNTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; GASTROINTESTINAL DISEASES; HEART VALVE DISEASES; HUMANS; HYDROCEPHALUS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PNEUMONIA; PROSTHESIS-RELATED INFECTIONS; RETROSPECTIVE STUDIES; STAPHYLOCOCCUS; VANCOMYCIN;

EID: 33750565386     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-006-9037-3     Document Type: Article

References (27)

1. Farreras P, Rozman C. Medicina interna, vol II, XIV Ed. Harcourt, S.A., Madrid. ISBN 84-8174-359-3. 2000;1645, 1709-10.
2. Ammirati M, Raimondi AJ. Cerebrospinal fluid shunt infections in children. A study on the relationship between the etiology of hydrocephalus, age at the time of shunt placement and infection rate. Child's Nerv Sys 1987;3:106-9.
3. Bayston R. Hydrocephalus shunt infections. J Antimicrob Chemother 1994; 34(Suppl. A):75-84.
4. Choux M, Genitori L, Lang D, Lena G. Shunt implantation: reducing the incidence of shunt infection. J Neurosurg 1992;77:875-80.
5. Ellenbogen RG, Goldmann DA, Winston KR. Group B Streptococcal infections of the central nervous system in infants with myelomeningocele. Surg Neurol 1988;29:237-42.
6. Vinchon M, Vallee L, Prin L, Desreumaux P, Dhellemmes P. Cerebro-spinal fluid eosinophilia in shunt infections. Neuropediatrics 1992;23:235-40.
7. Bafeltowska JJ, Buszman E, Mandat KM, Hawranek JK. Therapeutic vancomycin monitoring in children with hydrocephalus during treatment of shunt infections. Surg Neurol 2004 Aug;62(2):142.
8. Bourgeois M, Sainte-Rose C, Cinalli G, Maixner W, Malucci C, Zera M, et al. Epilepsy in children with shunted hydrocephalus. J Neurosurg 1999 Feb;90(2):274-81.
9. Bennett DR, editor. Drug evaluations subscription. Chicago, IL: American Medical Association, Winter 1992.
10. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharmaceut 1981;9:503-12.
11. Fernandez de Gatta MM, Fruns I, Calvo MV, Lanao JM, Dominguez-Gil A. Influence of pharmacokinetic model on vancomycin peak concentration targets. Ther Drug Monit 1996 Apr;18(2):145-8.
12. Odenholt-Tornqvist I, Löwdin E, Cars C. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob Agents Chemother. 1992 sep;36(9):1852-8.
13. Soy D, Badia JR, Torres A. Antibiotic Dosage Regimens in Respiratory Tract Infections in the pharmacokinetic/pharmacodynamic era. Curr Respiratory Med Rev 2006;2:89-97.
14. Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ, Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987 Mar;31(3):393-7.
15. Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosage regimes: one- versus two-compartment Bayesian models. Ther Drug Monit 1989;11:450-4.
16. Albrecht LM, Rybak MJ, Boike SC, Pancorbo S. Comparison of serum sampling methods for determining vancomycin dosage regimes. Ther Drug Monit 1988;10:85-90.
17. Walson PD. Therapeutic drug monitoring in special populations. Clin Chem 1998;44(2):415-9.
18. Evans WE, Schentag JJ, Jusko WJ. Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Spokane, Applied Therapeutics, Inc. 1992.
19. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993 May;24(5):362-79.
20. DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 2004 Sep;58(3):259-68.
21. Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988 Jun;32(6):848-52.
22. PachoreK RE, Wood F. Vancomycin half-life in a patient with hepatic and renal dysfunction. Clin Pharm 1991;10:297-300.
23. Soto J, Alsar MJ, Sacristan JA. Initial dosage of vancomycin in neutropenic hematologic patients. Sangre (Barc) 1992 Jun; 37(3):181-4.
24. Tomás R, Soy D, García-Peláez M, Cardenete J, Quintana E, Mangues MA. High dose requirements of vancomycin in multiple trauma adult patients in intensive care units [Abstract]. Pharm World Sci 2000;22(1):28 [A47].
25. Pea F, Porreca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000 Mar;45(3):329-35.
26. Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990 May;34(5):792-5.
27. Conil JM, Favarel H, Laguerre J, Brouchet A, Chabanon G, Cazal L, et al. Continuous administration of vancomycin in patients with severe burns. Presse Med 1994 Nov 5; 23(34):1554-8.